文献速递免疫规划慢病防控与筛查

系统性红斑狼疮患者对SARS-CoV-2疫苗的犹豫及接种后疾病发作

Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus.
PubMed 文献 · Vaccine · 2022-09-06

研究纳入914例系统性红斑狼疮(SLE)患者,追踪其SARS-CoV-2疫苗接种状态并回顾接种后6周内SLE发作情况。449例(49.1%)接种两剂疫苗,接种率显著低于成人普通人群(77.8%;p<0.001)。接种与SLE发作无显著关联(OR 1.40[0.81-2.43];p=0.23),但接种前活动性狼疮血清学及关节炎/盘状皮损史与接种后发作相关。

要点

  • SLE患者SARS-CoV-2疫苗接种率49.1%,显著低于成人普通人群的77.8%(p<0.001)。
  • 接种组SLE发作37例(8.2%),未接种对照组28例(6.2%),OR 1.40[0.81-2.43];p=0.23,无显著差异。
  • 接种前活动性狼疮血清学(OR 2.63[1.05-6.62];p=0.04)、关节炎史(OR 2.71[1.05-7.00];p=0.04)及盘状皮损史(OR 4.73[1.90-11.8];p=0.001)与接种后发作相关。

核心结论

  • SLE患者对COVID-19疫苗接种的犹豫较常见;接种SARS-CoV-2疫苗与SLE发作无显著关联;接种前活动性狼疮血清学或关节炎/盘状皮损史者接种后更易发作。

研究设计与样本

  • 纳入符合ACR标准≥4条的SLE患者,追踪SARS-CoV-2疫苗接种状态,回顾性分析接种后6周SLE发作,比较接种与未接种及有无接种后发作患者的临床特征。

主要发现

  • 共914例成人SLE患者(女性92.5%,年龄48.6±14.0岁;SLE病程14.5±8.6年)。
  • 449例(49.1%)接种两剂SARS-CoV-2疫苗(61.5% BioNTech;38.5% CoronaVac)。
  • SLE接种率显著低于成人普通人群的77.8%(p<0.001)。
  • 接种组37例(8.2%)发生SLE发作(轻/中度34例,重度3例);等量随机匹配未接种对照组28例(6.2%)发作(轻/中度17例,重度11例)。
  • 接种组发作OR 1.40[0.81-2.43];p=0.23(校正年龄、性别、活动性血清学、SLE病程及泼尼松使用)。

关键数值与推荐

  • 接种组SLE发作37例(8.2%),未接种对照组28例(6.2%),OR 1.40[0.81-2.43];p=0.23,无显著差异。
  • 接种前活动性狼疮血清学与接种后发作相关:OR 2.63[1.05-6.62];p=0.04。
  • 关节炎史与接种后发作相关:OR 2.71[1.05-7.00];p=0.04。
  • 盘状皮损史与接种后发作相关:OR 4.73[1.90-11.8];p=0.001。
  • 接种犹豫者更多为高血压、有神经肌肉表现史,且器官损伤评分更高(1.10±1.45 vs 0.74±1.15;p<0.001),但多因素分析中均无显著关联。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the rate of SARS-CoV-2 vaccination and post-vaccination disease flares in patients with systemic lupus erythematosus (SLE). METHODS: Patients who fulfilled ≥ 4 of the ACR criteria for SLE were identified and their SARS-CoV-2 vaccination status was traced. Flares of SLE at 6-week post-vaccination were reviewed retrospectively. Clinical characteristics of patients with and without vaccination, and those who did or did not experience post-vaccination flares were compared by statistical analyses. RESULTS: 914 adult patients with SLE were studied (92.5 % women, age 48.6 ± 14.0 years; SLE duration 14.5 ± 8.6 years). Two doses of the SARS-Cov-2 vaccines (61.5 % BioNTech; 38.5 % CoronaVac) were received by 449 (49.1 %) patients. The vaccination rate in SLE was significantly lower than that of the adult general population (77.8 %; p < 0.001) at the time of data analysis. Patients who were hesitant for vaccination were more likely to be hypertensive, have a history of neuromuscular manifestations, and a significantly higher organ damage score (1.10 ± 1.45 vs 0.74 ± 1.15; p < 0.001). However, none of these factors were significantly associated with vaccine hesitancy on multivariate analysis. Among 449 vaccinated patients, 37(8.2 %) experienced SLE flares: mild/moderate in 34; severe in 3. In an equal number of unvaccinated SLE controls randomly matched for the post-vaccination observation period, 28(6.2 %) had SLE flares: mild/moderate in 17; severe in 11 (odds ratio [OR] for flare in vaccinated patients 1.40[0.81-2.43]; p = 0.23, adjusted for age, sex, active serology, SLE duration and prednisolone use). In vaccinated patients, logistic regression revealed that active lupus serology before vaccination (OR 2.63[1.05-6.62]; p = 0.04) and a history of arthritis (OR 2.71[1.05-7.00]; p = 0.04) or discoid skin lesion (OR 4.73[1.90-11.8]; p = 0.001) were associated with SLE flares following vaccination, adjusted for confounders. CONCLUSION: Hesitancy for COVID-19 vaccination is common in SLE patients. Vaccination against SARS-CoV-2 is not significantly associated with increased SLE flares. Patients with active SLE serology or a history of arthritis/discoid lesion are more likely to flare after vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mok CC, Chan KL, Tse SM, et al. Hesitancy for SARS-CoV-2 vaccines and post-vaccination flares in patients with systemic lupus erythematosus. Vaccine. 2022. PMID: 36085256. doi:10.1016/j.vaccine.2022.08.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。